Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEU-723 Phase 1 Study in Healthy Subjects
NCT05633745Phase 1Terminated
- Sponsor
- Neuron23
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing NEU-723 with Placebo (2 arms). Primary endpoint: Safety and tolerability of single and multiple oral doses up to 7 days. Started Jan 2023; status: terminated.
02
Drugs
NEU-723
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05633745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633745.